Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 10, 2016 5:38 PM ET


Company Overview of Ventria Bioscience, Inc.

Company Overview

Ventria Bioscience, Inc., a biotechnology company, develops, manufactures, and markets health and nutrition products. The company focuses on developing products in human nutrition and human therapeutics. Its product portfolio includes lactoferrin and lysozyme glycoproteins, which are used for gastrointestinal health, dietary management of acute diarrhea, treatment of topical infections and inflammations, and alleviation of fungal infections. The company also provides BioShare program for researchers, which provides access to a supply of recombinant proteins and peptides for research ideas. Ventria Bioscience, Inc. was founded in 1993 and is based in Fort Collins, Colorado.

PO Box 273330

Fort Collins, CO 80527

United States

Founded in 1993





Key Executives for Ventria Bioscience, Inc.

Chief Executive Officer, President and Director
Vice President of Finance & Business Development
Chief Medical Officer
Age: 66
Corporate General Counsel
Chairman Emeritus and Member of Scientific Network
Compensation as of Fiscal Year 2015.

Ventria Bioscience, Inc. Key Developments

Ventria Bioscience Appoints Seymour Fein as Chief Medical Officer

Ventria Bioscience announced that Seymour Fein, M.D., has been appointed as the company's new Chief Medical Officer. Dr. Fein will be responsible for the company's clinical development and medical affairs functions. Dr. Fein began his career at Hoffmann-La Roche Ltd. as a senior research physician and was responsible for a clinical development program that led to U.S. Food and Drug Administration (FDA) approval of recombinant interferon-alpha for cancer treatment. Dr. Fein was also the medical director of Bayer Healthcare Pharmaceuticals (U.S.) where he was responsible for therapeutic areas including gastroenterology, oncology, and cariology.

Similar Private Companies By Industry

Company Name Region
Harta Corporation United States
Zebra Biologics, Inc. United States
Aphton Corp. United States
Advanced AgriTraits LLC United States
Odyssey Thera, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ventria Bioscience, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at